one of the most potent endogenous vasodilators in coronary arteries, and appeared to show more potent vasodilating effects on the smalldiameter resistant vessels than the large-diameter conduit vessels. The purpose is to study the roles of CGRP in the coronary microcirculation and energy metabolism under ischemic conditions elicited by endothlin-1 (ET-1). Methods: We observed the effects of CGRP on the coronary microcirculation and energy metabolism in isolated beating rat hearts. Microcirculation was observed by an intravital fluorescence videomicroscope system and energy metabolism was evaluated under 31P-magnetic resonance spectroscopy (31P-MRS) after coronary microvessels were pre-contracted with ET-1(30 pmol), a potent intrinsic vasoconstrictor of small arterioles in myocardium. Results: Cumulative application of CGRP (3-1000 pmol) elicited both dose-dependent reduction in total coronary perfusion resistance (TPR) and simultaneous vasodilation of arterioles of 10-40 μm in diameter (maximal % relaxation was 62%, n = 7). The ED50 value of CGRP was 30 pmol, about 5000-fold smaller than that of nitroglycerin. Administration of CGRP (100 pmol) decreased TPR (− 34%), increased heart rate (+17%), cardiac dP/dt (+76%), work index (+57%), ATP (+21%) and highenergy phosphates (PCr) (+ 45%) significantly (p b 0.05, n = 14) in myocardium. Conclusion: CGRP relaxed the coronary microvessels, improved the myocardial high-energy metabolism and enhanced the cardiac contractility in the ischemic myocardium, suggesting that the CGRP may play beneficial roles in myocardial ischemia elicited by ET-1. Introduction: Scleroderma (SSc) is an autoimmune connective tissue disease of unknown aetiology. Pulmonary involvement including the development of pulmonary arterial hypertension (PAH) is characterised by vascular remodelling, collagen deposition and expression of connective tissue growth factor (CTGF). CD14+ monocytes can differentiate into spindle shaped cells termed 'fibrocytes'. Fibrocytes express haematopoietic and mesenchymal markers including collagen, and amplify inflammatory/immune responses via antigen presentation and chemokine secretion. Fibrocyte differentiation is enhanced by fibrogenic cytokines including PDGF. The role fibrocytes play in promoting PAH in SSc is unknown. Methods: CD14+ PBMCs were isolated from SSc and healthy donor blood. Fibrocyte differentiation in the presence of MCSF and/or ET-1 was assessed after 14 days. The effect of endothelin receptor (ETR) antagonists (selective/dual) on fibrocyte differentiation (n = 6) was investigated. SSc and control fibrocyte secretomes were assessed by ELISA (n = 6), and the effects on fibroblast-mediated gel contraction determined. Results: MCSF and ET-1 alone and in combination induced fibrocyte differentiation (P b 0.05). SSc fibrocytes exhibited enhanced differentiation from CD14+ PBMCs than healthy control donors in response to MCSF (P b 0.05), ET-1 (P b 0.05) and in combination (P b 0.01). ETR antagonists BQ123 (ETRA), BQ788 (ETRB) and Bosentan (ETRA/B) inhibited MCSF induced fibrocyte differentiation. CTGF secretion was elevated in SSc compared to control fibrocytes (P b 0.05) cultured with MCSF.
Conditioned media from SSc fibrocytes promoted gel contraction by control pulmonary fibroblasts (P b 0.05). Discussion CD14+ SSc PBMCs readily differentiate into fibrocytes in response to ET-1 and MCSF via ETRA and ETRB. Our data suggests that fibrocytes contribute to the development of PAH in SSc via a paracrine mechanism modulating the functional activities of resident tissue fibroblasts. 
